Literature DB >> 4081060

Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse.

J M Young, P J Maloney, S N Jubb, J S Clark.   

Abstract

Although the platelets of the mouse are refractory to the direct effects of platelet-activating-factor (PAF), tail vein injection of 10-150 micrograms/kg PAF produces lethal anaphylactic shock. Sensitivity varies with strain and source: Swiss Webster mice show a range of sensitivity and DBA/2 (complement C5-deficient) mice are very resistant. At lethal doses of PAF, animals show labored respiration and general depression; death occurs within 15-45 min. Dexamethasone administered at least 1.5 hr prior consistently protects, whereas the cyclooxygenase inhibitors do not. Antihistamines, adrenergic antagonists, and methysergide have no effect, but cyproheptadine is partially protective at near lethal doses. Calcium entry blockers and calcium chelators, tetracycline and chlortetracycline are partially protective at very high doses consistent with non-specific effects on calcium dependent processes. The arachidonic acid lipoxygenase inhibitors BW755c, phenidone, nordihydroguaiaretic acid and diphenyldisulfide provide nearly complete protection after oral administration of 50-200 mg/kg. Phosphodiesterase inhibitors and dapsone are also effective orally. The leukotriene antagonist FPL55712 administered intraperitoneally (10 mg/kg) 5 min. prior to PAF challenge provides almost complete protection. PAF-induced mortality in the mouse represents a small animal model of systemic anaphylaxis particularly useful for the systemic testing of arachidonic acid lipoxygenase inhibitors and leukotriene antagonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4081060     DOI: 10.1016/0090-6980(85)90018-8

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  10 in total

1.  Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration.

Authors:  J L Wallace; B J Whittle
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

2.  Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.

Authors:  T Yamada; M Saito; T Mase; H Hara; H Nagaoka; K Murase; K Tomioka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Altered inflammatory responses in leukotriene-deficient mice.

Authors:  J L Goulet; J N Snouwaert; A M Latour; T M Coffman; B H Koller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor.

Authors:  Zhili Xu; Jeffrey S Smith; Jie Tian; Andrew P Byrnes
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

5.  Platelet activating factor amplifies human neutrophil adherence to bovine endothelial cells: evidence for a lipoxygenase dependent mechanism.

Authors:  B Damtew; P J Spagnuolo
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

6.  Paf-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors.

Authors:  M Criscuoli; A Subissi
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

7.  In vivo responses of mouse blood cells to platelet-activating factor (PAF): role of the mediators of anaphylaxis.

Authors:  D Kelefiotis; C Vakirtzi-Lemonias
Journal:  Agents Actions       Date:  1993-11

8.  Catecholamines released from the adrenal medulla exert a compensatory, protective effect at beta 2-adrenoceptors against Paf-induced death in mice.

Authors:  M Criscuoli; A Subissi
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

9.  Pharmacologic modulation of PAF-induced mortality in mice.

Authors:  R P Carlson; L O'Neill-Davis; J Chang
Journal:  Agents Actions       Date:  1987-08

10.  Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses.

Authors:  R S Byrum; J L Goulet; R J Griffiths; B H Koller
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.